First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.
;
Hermann
Sorgho
;
Innocent
Valea
;
Marc Christian
Tahita
;
William
Kaboré
;
Sayouba
Ouédraogo
;
Yara
Sandrine
;
Robert Tinga
Guiguemdé
;
Jean Bosco
Ouédraogo
;
Mary J
Hamel
;
Simon
Kariuki
;
Chris
Odero
;
Martina
Oneko
;
Kephas
Otieno
;
Norbert
Awino
;
Jackton
Omoto
;
John
Williamson
;
Vincent
Muturi-Kioi
;
Kayla F
Laserson
;
Laurence
Slutsker
;
Walter
Otieno
;
Lucas
Otieno
;
Otsyula
Nekoye
;
Stacey
Gondi
;
Allan
Otieno
;
Bernhards
Ogutu
;
Ruth
Wasuna
;
Victorine
Owira
;
David
Jones
;
Agnes Akoth
Onyango
;
Patricia
Njuguna
;
Roma
Chilengi
;
Pauline
Akoo
;
Christine
Kerubo
;
Jesse
Gitaka
;
Charity
Maingi
;
Trudie
Lang
;
Ally
Olotu
;
Benjamin
Tsofa
;
Philip
Bejon
;
Norbert
Peshu
;
Kevin
Marsh
;
Seth
Owusu-Agyei
;
Kwaku Poku
Asante
;
Kingsley
Osei-Kwakye
;
Owusu
Boahen
;
Samuel
Ayamba
;
Kingsley
Kayan
;
Ruth
Owusu-Ofori
;
David
Dosoo
;
Isaac
Asante
;
George
Adjei
;
George
Adjei
;
Daniel
Chandramohan
;
Brian
Greenwood
;
John
Lusingu
;
Samwel
Gesase
;
Anangisye
Malabeja
;
Omari
Abdul
;
Hassan
Kilavo
;
Coline
Mahende
;
Edwin
Liheluka
;
Martha
Lemnge
;
Thor
Theander
;
Chris
Drakeley
;
Daniel
Ansong
;
Tsiri
Agbenyega
;
Samuel
Adjei
;
Harry Owusu
Boateng
;
Theresa
Rettig
;
John
Bawa
;
Justice
Sylverken
;
David
Sambian
;
Alex
Agyekum
;
Larko
Owusu
;
Francis
Martinson
;
Irving
Hoffman
;
Tisungane
Mvalo
;
Portia
Kamthunzi
;
Ruthendo
Nkomo
;
Albans
Msika
;
Allan
Jumbe
;
Nelecy
Chome
;
Dalitso
Nyakuipa
;
Joseph
Chintedza
;
W Ripley
Ballou
;
Myriam
Bruls
;
Joe
Cohen
;
Yolanda
Guerra
;
Erik
Jongert
;
Didier
Lapierre
;
Amanda
Leach
;
Marc
Lievens
;
Opokua
Ofori-Anyinam
;
Johan
Vekemans
;
Terrell
Carter
;
Didier
Leboulleux
;
Christian
Loucq
;
Afiya
Radford
;
Barbara
Savarese
;
David
Schellenberg
;
Marla
Sillman
;
Preeti
Vansadia
;
(2011)
First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.
The New England journal of medicine, 365 (20).
pp. 1863-1875.
ISSN 0028-4793
DOI: 10.1056/NEJMoa1102287
BACKGROUND: An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate malaria vaccine RTS,S/AS01 is being conducted in seven African countries. METHODS: From March 2009 through January 2011, we enrolled 15,460 children in two age categories--6 to 12 weeks of age and 5 to 17 months of age--for vaccination with either RTS,S/AS01 or a non-malaria comparator vaccine. The primary end point of the analysis was vaccine efficacy against clinical malaria during the 12 months after vaccination in the first 6000 children 5 to 17 months of age at enrollment who received all three doses of vaccine according to protocol. After 250 children had an episode of severe malaria, we evaluated vaccine efficacy against severe malaria in both age categories. RESULTS: In the 14 months after the first dose of vaccine, the incidence of first episodes of clinical malaria in the first 6000 children in the older age category was 0.32 episodes per person-year in the RTS,S/AS01 group and 0.55 episodes per person-year in the control group, for an efficacy of 50.4% (95% confidence interval [CI], 45.8 to 54.6) in the intention-to-treat population and 55.8% (97.5% CI, 50.6 to 60.4) in the per-protocol population. Vaccine efficacy against severe malaria was 45.1% (95% CI, 23.8 to 60.5) in the intention-to-treat population and 47.3% (95% CI, 22.4 to 64.2) in the per-protocol population. Vaccine efficacy against severe malaria in the combined age categories was 34.8% (95% CI, 16.2 to 49.2) in the per-protocol population during an average follow-up of 11 months. Serious adverse events occurred with a similar frequency in the two study groups. Among children in the older age category, the rate of generalized convulsive seizures after RTS,S/AS01 vaccination was 1.04 per 1000 doses (95% CI, 0.62 to 1.64). CONCLUSIONS: The RTS,S/AS01 vaccine provided protection against both clinical and severe malaria in African children. (Funded by GlaxoSmithKline Biologicals and the PATH Malaria Vaccine Initiative; RTS,S ClinicalTrials.gov number, NCT00866619 .).
-
picture_as_pdf - nejmoa1102287.pdf
-
subject - Published Version
-
- Available under Creative Commons: Attribution-NonCommercial-No Derivative Works 3.0